SMN functions via recognition of arginine symmetric-dimethylated proteins by its Tudor domain, and scarcity of SMN leads to Spinal Muscular Atrophy (SMA). Here we report a potent and selective antagonist targeting the Tudor domain of SMN. This compound could inhibit the interaction between SMN and R1810me2s-POLR2A mimicking the SMN depletion results, thus this SMN antagonist could be used as an efficient tool to better understand SMN's biological functions and molecular etiology in SMA.
SMN is a core component of the SMN complex, which is essential for biogenesis of small nuclear ribonucleoproteins (snRNPs) by assembling the heptameric Sm ring onto spliceosomal snRNA 1 . The Tudor domain of SMN ( Fig. 1a ) binds to arginine symmetric-dimethylated (Rme2s) Sm proteins, and this interaction plays a critical role in snRNP assembly 2, 3 . Homozygous deletion or mutation of SMN coding gene is responsible for SMA 4 , the most common genetic cause of infant death with a frequency of 1 in ~10,000 births 5 . In addition to its role in snRNP assembly, SMN is also involved in regulation of nuclear architecture 6, 7 , local axonal translation in neurons 8 and transcription termination 9 . SMN interacts with symmetric-dimethylated R1810 at the C-terminal domain (CTD) of RNA polymerase II (RNAP II) subunit POLR2A (R1810me2s-POLR2A) via its Tudor domain to regulate transcription termination 9 . In the SMA patients, abnormal transcription termination such as pause of RNAP II and R-loop (DNA-RNA hybrids) accumulation in the termination region may facilitate neurodegeneration 9 . All in all, SMN functions in different biological pathways, and the Tudor domain of SMN plays a critical role in executing these functions by mediating arginine methylation dependent interactions.
In spite of the extensive study of SMN and its associated SMA disease, it is still unclear how SMN protects motor neurons in the spinal cord against degeneration. To this end, we set out to design SMN-selective chemical probes that would specifically occupy the methyl-arginine binding pocket and disrupt the Tudor domain-mediated and arginine methylation-dependent interactions. In this study, we obtained an SMN-selective antagonist by serendipity when we tried to screen inhibitors against the histone H3K9me3 binding tandem Tudor domain (TTD) of UHRF1 ( Fig. 1b and Supplementary Fig. 1a ). In this fluorescence-based peptide displacement screen for UHRF1, we found 5 hits, among which compound 1 was confirmed by Isothermal Titration Calorimetry (ITC) (K d ~16 µM, Supplementary Fig. 1b and 1c ). As we know, many proteins bind to lysine and arginine methylated histones/proteins, including the Tudor Royal superfamily (Tudor, Chromodomain, PWWP and MBT) of proteins and some CW and PHD domain containing proteins [10] [11] [12] [13] , and all of these proteins utilize an aromatic cage to recognize the methyl-lysine or methyl-arginine residue. In order to investigate the binding selectivity of compound 1, we screened it against selected methyl-arginine or methyl-lysine-binding Tudor domains and methyl-lysine-binding non-Tudor domains (Fig. 1c) . UHRF1_TTD was the only assayed methyl-lysine binder that measurably bound to compound 1. Intriguingly, compound 1 bound more tightly to the Tudor domains of SMN, SMNDC1, and TDRD3 than to UHRF1_TTD ( Fig. 1c and Supplementary Fig. 2 ). SMN, SMNDC1 and TDRD3 are the only three known methyl-arginine binding single Tudor proteins. Moreover, the highly homologous Tudor domains of SMN and SMNDC1 bound to compound 1 with a ~4-fold selectivity over that of TDRD3 ( Fig.   1c ).
In order to understand the structural basis of the compound 1 recognition by these reader proteins, we determined the crystal structures of compound 1 in complex with SMN, TDRD3 and UHRF1, respectively ( Fig. 2 Table 1 ). In the SMNcompound 1 complex structure, compound 1 bound to the aromatic cage formed by W102, Y109, Y127 and Y130, which otherwise accommodates dimethyl-arginine ( Fig. 2a-2c ). W102 and Y130 sandwich the compound 1 rings. In addition, compound 1 forms a hydrogen bond between its imine group and the side chain of N132. This hydrogen bond boosts the ligand binding ability of SMN because mutating N132 to alanine significantly reduced its binding affinity ( Fig. 2e ). In the TDRD3-compound 1 structure, the binding mode is largely conserved ( Supplementary Fig.   3 ), but Y566 of TDRD3 might not stack against the compound as effectively as W102 in SMN ( Fig. 2d and Supplementary Fig. 5 ), which may explain weaker affinity of TDRD3 ( Fig. 1c ).
, Supplementary Figs. 3/4 and Supplementary
Although we did not determine the corresponding complex structure of SND1, structure-based sequence alignment revealed that the W102 position of SMN corresponds to F740 of SND1 ( Fig.   2d and Supplementary Fig. 5 ). The W102F SMN mutant, like SND1, bound to compound 1 only weakly ( Fig. 2e ). In addition, W102A and Y130A mutants of SMN did not bind to compound 1 ( Fig. 2e ). This lack of binding is consistent with our failure to observe binding for the other tested proteins. Additional considerations apply to UHRF1 and will be discussed later. On the other hand, cage mutations Y109A and Y127A weakened, but did not abrogate binding to compound 1 ( Fig. 2e ). Hence, the sandwich stacking interactions of compound 1 by W102 and Y130 play a critical role in the compound 1 recognition.
To uncover the specific interaction between UHRF1_TTD and compound 1, we also solved the complex structure of UHRF1_TTD-compound 1 ( Supplementary Fig. 4 ). Two UHRF1_TTD molecules are present in each asymmetric unit of the UHRF1-compound 1 complex structure ( Supplementary Fig. 4a ), but we only observed the expected disc-shaped electron density of compound 1 in the histone H3K9me3-binding cage of one UHRF1_TTD molecule, while we found a differently shaped blob in the aromatic cage of the other protein chain ( Supplementary   Fig. 4b ). In the complex structure of UHRF1_TTD-PHD and an H3K9me3 peptide (PDB code: 3ASK), the arginine residue R296 in the linker between the TTD and PHD of UHRF1 is found in a pocket formed by D142, E153, A208, M224, W238 and F278 from both TTD N and TTD C 14 ( Supplementary Figs. 1a and 4c ). R296 is fixed in the pocket by forming two salt bridges with D142. Intriguingly, we found the expected disc-shaped density peaks consistent with compound 1 in the arginine-binding pockets of both UHRF1_TTD chains. The compound 1 molecule is stacked between the indole ring system of W238 and the guanidinium group of R209 ( Supplementary Fig. 4d ).
Several lines of evidence suggested that the arginine binding pocket is the major binding site and the methyl-lysine-binding aromatic cage is just a minor or non-specific binding site: 1. When we mutated the aromatic cage residues that have been shown to be critical for histone H3K9me3 binding to alanine, the binding affinity is not affected significantly. In contrast, when we mutated the arginine binding pocket residues, the binding is totally disrupted ( Supplementary Fig. 4e ). 2.
The electron density inside the H3K9me3 aromatic cage is either smear and can be modelled in multiple orientations of compound 1, which implies that compound 1 does not bind to the cage specifically, or is of no defined density shape ( Supplementary Fig. 4b ). 3. The aromatic cage has a propensity to accommodate small molecules non-specifically. For instance, some buffer molecules have been found in the aromatic cage of TDRD3 15 . For the case of UHRF1_TTD, some ethylene glycol molecules from the crystallization buffer are found in the H3K9me3 aromatic cage and the arginine pocket of the apo-UHRF1_TTD structure 16 ( Supplementary Fig.   4f ). 4. In the SMN-compound 1 complex structure, compound 1 is stacked between the aromatic rings of W102 and Y130. However, the three aromatic residues in the aromatic cage of UHRF1 are perpendicular to each other, which could not stack the compound like SMN does ( Supplementary Fig. 4g ). Taken together, UHRF1 used the arginine binding pocket to specifically bind to compound 1, and this arginine binding pocket could serve as a novel therapeutic venue for designing potent small molecule allosteric regulators of the UHRF1 functions.
To explore structure-activity relationship between SMN and compound 1-like compounds, we procured commercially available analogs that include single, double and triple ring molecules and measured their affinities toward SMN and UHRF1, respectively ( Fig. 1d ). SMN bound to all four triple-ring compounds with affinities between 2.6 μ M to 31 μ M ( Fig. 1d and Supplementary   Fig. 6 ). The ligands have a 4-aminopyridine core in common, and none of these analogs are more potent than the original hit. A plausible orientation of compound 1, given the electron density, would entail a hydrogen bond between the 4-amino group and N132. Due to the electronic similarity between the N-methyl and 4-amino sites on the 4-aminopyridine core, we did not expect to resolve the orientation of compound 1 based on electron density alone, and could not exclude the possibility that the amino group would instead protrude into the solvent. Binding of 1-substituted pyridine cores to SMN would confirm that N132 does interact with the amino group and substituents on the pyridine nitrogen would point away from the Tudor domain, as larger 1-substituents would otherwise clash inside the aromatic cage. Indeed, our crystal structure of SMN in complex with compound 4 confirms that the imine group of compound 4 forms a hydrogen bond with N132 ( Supplementary Fig. 7a and 7b ).
In addition to compounds 1 and 4, SMN also bound to two of twelve double ring compounds, compounds 5 and 6 ( Fig. 1d and Supplementary Fig. 6 ). Both compounds retain the amino/imino group, which pinpoints the importance of the amino/imino group-mediated hydrogen bond in the compound binding and is consistent with our crystal structures of SMN in complex with compounds 1, 4, and 6 ( Fig. 2 and Supplementary Fig. 7 ). None of the single ring compounds bound to SMN, which may not be able to provide strong enough π -π stacking interactions to hold the compounds. UHRF1, however, did not bind to any other three-ring compounds, because the substituents on the pyridine nitrogen of these compounds are too large for the more enclosed arginine binding pocket of UHRF1.
We previously showed that R1810 in the CTD of the mammalian RNAP II subunit POLR2A is symmetrically dimethylated by PRMT5 and the R1810 methylated CTD directly recruits the Tudor domain protein SMN, which might contribute to the assembly of an R-loop resolving complex on the RNAP II CTD 9 . Hence, we asked whether these small molecule antagonists might be able to disrupt the interaction of SMN with RNAP II in vivo. To test this possibility, we treated the HEK293 cells with 20 to 40 µM of either compound 1 or compound 2 for 72 hours, and then performed immunoprecipitations using the cell extracts, which showed decreased levels of interaction between POLR2A and SMN, whereas no significant effect was observed for the cells treated with DMSO as a control (Fig. 3a) . These results demonstrate the inhibitory effects of the SMN-RNAP II interaction by the SMN small molecule antagonists. Since 20 µM of either compound 1 or compound 2 is enough to show significant inhibition of the interaction between SMN and POLR2A, we used this concentration in the following assays.
Our previous ChIP study has shown that SMN occupies the ACTN (β-actin) gene from its promoter to the termination regions with the highest level of occupancy at the 3′-end of the gene 9 .
PRMT5 depletion or POLR2A R1810 mutation leads to a decreased SMN occupancy 9 . To examine whether the SMN small molecule antagonists have any effects on the SMN occupancy at its target genes during transcription, the SMN ChIP assay was performed using the primers along the ACTN gene ( Fig. 3b ). Similar to the effects of PRMT5 depletion or POLR2A R1810 mutation, treatment of either compound 1 or compound 2 significantly reduced the levels of SMN along the ACTN gene ( Fig. 3c ). Given that POLR2A CTD R1810A mutation or depletion of SMN leads to the accumulation of RNPA II at genes 9 , SMN antagonists might have similar effects. To address this issue, we performed RNAP II ChIP experiments and found that adding 20 µM of either compound 1 or compound 2 (72h) significantly increased the occupancy levels of RNAP II at the promoter regions and 3′-end of the ACTB gene as detected by quantitative PCR (qPCR) (Fig. 3d ). These results indicate that SMN antagonists could cause the accumulation of RNAP II at both the promoter and 3′ pause site of its target genes.
Our previous studies demonstrated that PRMT5 or SMN depletion, or POLR2A R1810 mutation leads to the R-loop accumulation at the ACTB gene 9 . Here, we further confirmed that CRISPR/Cas9 mediated SMN knock-out increased the global R-loop accumulation in HEK293 cells as detected by immunofluorescence staining (Fig. 3e and 3f Consistently, treatment of either compound 1 or compound 2 significantly increased the R-loop signals at the 3′-end of the ACTB gene ( Fig. 3h ).
In summary, in this study, we identified some low micromolar antagonists of SMN, and compound 1 shows >4-fold selectivity over other tested methyl-lysine or arginine binding domains. Our structural and mutagenesis studies provide mechanistic insights into the selectivity of compound 1 for SMN. Our cellular results display that SMN antagonists prevent SMN interaction with R1810me2s-POLR2A, resulting in the over-accumulation of active RNAP II and R-loop, mimicking the SMN depletion results. Thus, in addition to the antisense, RNAi and CRISPR/Cas9 techniques, these potent SMN antagonists may be used as efficient tools in the study of SMN biology and its related neurological diseases.
Methods

Protein expression and purification
The coding DNA fragments of following Tudor domains were cloned into pET28-MHL vector: 
Isothermal Titration Calorimetry (ITC)
For the ITC measurement, the concentrated proteins were diluted into 20 mM Tris-Cl, pH 7.5, 150 mM NaCl (ITC buffer); the lyophilized compounds were dissolved in the same buffer, and the pH value was adjusted by adding 2 M NaOH or 2 M HCl. The compounds that could not be dissolved in the ITC buffer were dissolved in DMSO with the accessible highest concentration. 
Data collection and structure determination
The program PHASER 18 was used for molecular replacement (MR) when needed. Models were interactively rebuilt, refined and validated using COOT 19 , REFMAC 20 and MOLPROBITY 21, 22 software, respectively. MarvinSketch (Chemaxon.com) was used for the calculation of some SMILES strings during preparation of small molecule geometry restraints. PDB_EXTRACT 23 and CCTBX 24 
Immunoprecipitation (IP) and Western blot
Immunoprecipitation was performed with RIPA buffer (140 mM NaCl, 10 mM Tris-Cl, pH7.6-8, 1% Triton, 0.1% sodium deoxycholate, 1 mM EDTA) containing protease inhibitors (Roche, 05892791001) and Benzonase (Sigma, E1014) as described previously 9 Primary antibodies (POLR2A, Abcam monoclonal antibody, ab5408; SMN, Santa Cruz polyclonal antibody H-195, sc-15320; ACTB, Sigma, A5441) were used at 1:2,000 to 1:5,000 dilutions for incubation overnight followed by three times washes with RIPA buffer, and horseradish peroxidase-conjugated goat anti-mouse or-rabbit secondary antibodies (Jackson ImmunoResearch, 211-032-171 or 115-035-174) were used at 1:10,000 dilutions for incubation 1 h followed by three times washes with RIPA buffer. Blots were developed using SuperSignal
West Pico or Femto (Thermo Scientific, 34079 or 34094).
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the EZ-ChIP™ A -Chromatin Immunoprecipitation Kit (Millipore, 17-371) according to manufacturer's instruction. Antibodies were used with a range of 1-2 μ g,
and IgG (Millipore polyclonal antibody, 12-370) was used as a background control. After immunoprecipitation, genomic DNA was de-crosslinked in ChIP elution buffer containing 5 M NaCl at 65 °C overnight and purified with the Qiaex II kit (Qiagen, 20021) and eluted in water for PCR amplification. Immunoprecipitated and input DNAs were used as templates for qPCR.
The qPCR primer sequences for ACTB gene are the same as described earlier 9 . 
Immunofluorescence and microscopic R-loop quantification
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